Clarivate to Sell Life Sciences Unit to Altaris for $600M
Clarivate announces a $600 million deal to divest its Life Sciences & Healthcare business to private equity firm Altaris.
Clarivate (CLVT) announced Monday it has agreed to sell its Life Sciences & Healthcare business unit to Altaris, a healthcare-focused private equity firm, for $600 million in a deal that marks a significant strategic pivot for the data and analytics company.
The divestiture signals Clarivate's intent to streamline its portfolio and sharpen focus on its remaining core operations. By offloading the Life Sciences & Healthcare segment, the company appears to be repositioning itself around its intellectual property and academia-facing businesses, a move that analysts may view as an effort to reduce complexity and improve margins.
Read more FanDuel Predicts Promo: $25 Bonus for Brewers vs. Pirates →
Altaris, which specializes in healthcare industry investments, stands to gain a well-established life sciences data platform with existing client relationships across pharmaceutical and medical research sectors. The acquisition gives the private equity firm a sizeable asset to grow outside of public market pressures.
The $600 million price tag represents a notable transaction in the healthcare data space, where demand for specialized analytics and intelligence tools has remained strong. How Clarivate deploys the proceeds — whether toward debt reduction, share buybacks, or reinvestment in remaining divisions — will be closely watched by investors in the coming weeks.
Continue reading at Yahoo Finance.
